These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 9523750

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).
    O'Brien SH, Ritchey AK, Smith KJ.
    Pediatr Blood Cancer; 2007 Feb; 48(2):173-80. PubMed ID: 16550529
    [Abstract] [Full Text] [Related]

  • 4. Treatment of acute immune thrombocytopenic purpura.
    Tarantino MD, Goldsmith G.
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):28-35. PubMed ID: 9523747
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [Abstract] [Full Text] [Related]

  • 8. Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
    Cooper N.
    Hematol Oncol Clin North Am; 2009 Dec; 23(6):1317-27. PubMed ID: 19932436
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacoeconomics of therapy for ITP: steroids, i.v.Ig, anti-D, and splenectomy.
    Adams JR, Nathan DP, Bennett CL.
    Blood Rev; 2002 Mar; 16(1):65-7. PubMed ID: 11913999
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical experience with anti-D in the treatment of idiopathic thrombocytopenic purpura.
    Scaradavou A, Bussel JB.
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):52-7. PubMed ID: 9523749
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.
    Freiberg A, Mauger D.
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):23-7. PubMed ID: 9523746
    [Abstract] [Full Text] [Related]

  • 20. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
    Blackhouse G, Xie F, Levine MA, Campbell K, Assasi N, Gaebel K, O'Reilly D, Tarride J, Goeree R.
    J Popul Ther Clin Pharmacol; 2012 Jan; 19(2):e166-78. PubMed ID: 22580389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.